Overview

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Status:
Not yet recruiting

Trial end date:
2023-08-15

Target enrollment:

Participant gender:

Summary

TNM002 Injection is a recombinant fully human native monoclonal antibody (mAb) against tetanus toxin and is currently under development for indication of prophylaxis against tetanus.

Phase:

Phase 3

Details

Lead Sponsor:

Trinomab Biotech Co., Ltd.

Treatments:

Antibodies
Immunoglobulins
Immunoglobulins, Intravenous